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Abstract
Substantial exposure to Borrelia miyamotoi occurs through bites from Ixodes ricinus ticks in the Netherlands, which also transmit Borrelia
burgdorferi sensu lato and Anaplasma phagocytophilum. Direct evidence for B. miyamotoi infection in European populations is scarce. A ﬂu-like
illness with high fever, resembling human granulocytic anaplasmosis, has been attributed to B. miyamotoi infections in relatively small groups.
Borrelia miyamotoi infections associated with chronic meningoencephalitis have also been described in case reports. Assuming that an IgG
antibody response against B. miyamotoi antigens reﬂects (endured) infection, the seroprevalence in different risk groups was examined. Sera
from nine out of ten conﬁrmed B. miyamotoi infections from Russia were found to be positive with the recombinant antigen used, and no
signiﬁcant cross-reactivity was observed in secondary syphilis patients. The seroprevalence in blood donors was set at 2.0% (95% CI 0.4–
5.7%). Elevated seroprevalences in individuals with serologically conﬁrmed, 7.4% (2.0–17.9%), or unconﬁrmed, 8.6% (1.8–23%), Lyme
neuroborreliosis were not signiﬁcantly different from those in blood donors. The prevalence of anti-B. miyamotoi antibodies among forestry
workers was 10% (5.3–16.8%) and in patients with serologically unconﬁrmed but suspected human granulocytic anaplasmosis was 14.6%
(9.0–21.8%); these were signiﬁcantly higher compared with the seroprevalence in blood donors. Our ﬁndings indicate that infections with
B. miyamotoi occur in tick-exposed individuals in the Netherlands. In addition, B. miyamotoi infections should be considered in patients
reporting tick bites and febrile illness with unresolved aetiology in the Netherlands, and other countries where I. ricinus ticks are endemic.
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Introduction
Borrelia miyamotoi belongs to the relapsing fever group of the
Borrelia genus [1]. Agents of relapsing fever spirochaetes are
transmitted between vertebrates by different vectors; for
example, Borrelia duttonii and Borrelia hermsii are transmitted by
soft ticks and Borrelia recurrentis is transmitted by the human
body louse [2–4]. Interestingly, B. miyamotoi is transmitted by
the same vectors as Borrelia burgdorferi senso lato and
Anaplasma phagocytophilum, the causative agents of Lyme
borreliosis (LB) and human granulocytic anaplasmosis (HGA),
respectively [4,5]. In Europe, Asia and North America,
B. miyamotoi infection rates in Ixodes persulcatus, Ixodes scapu-
laris, Ixodes paciﬁcus and Ixodes ricinus range between 0.5% and
5% [1,5–10]. In the Netherlands, the infection rate of I. ricinus is
2.4–4.7% in all three life stages [11]. The presence of
B. miyamotoi in wild rodents indicates enzootic circulation in
the Netherlands (S. Jahfari, unpublished observations). Fur-
thermore, a recent study estimated that in the Netherlands
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annually, approximately 200 000 people are bitten by ticks
infected with B. burgdorferi s.l. and 36 000 by B. miyamo-
toi-infected ticks [11]. Additionally, exposure to both Lyme
and relapsing fever Borrelia by co-infected ticks occurs in at least
9000 people annually. This substantial exposure raises the
question to what extent B. miyamotoi leads to human disease in
the general population.
Currently, the clinical symptoms of B. miyamotoi infections
are undeﬁned, and validated supportive laboratory diagnostic
tests are lacking. Infections with other members of the
relapsing fever Borreliae are characterized by ﬂu-like illness and
one or more relapse episode(s) of bacteraemia and fever.
Borrelia miyamotoi infections in humans were ﬁrst reported in
Russian patients suspected of LB (Table 1). Fifty-one patients
with suspected LB had ampliﬁable B. miyamotoi DNA in venous
blood samples, and most tested positive by commercial IgM
and IgG serology assays used for LB diagnosis. This test
consisted of a mixture of whole cell antigens from Borrelia
afzelii, B. burgdorferi and Borrelia garinii [12]. A potentially
severe complication of B. miyamotoi infection is meningoen-
cephalitis. The ﬁrst American and European meningoenceph-
alitis case reports for well-documented B. miyamotoi infection
were described in severely immunocompromised patients
[13,14] and B. miyamotoi was detected in cerebrospinal ﬂuid
with the use of microscopy and PCR assays. In another study,
two cases of B. miyamotoi infection were initially mistaken for
HGA [15] on the basis of their clinical manifestations after a
tick bite (Table 1). Disease caused by an infection with
B. miyamotoi may be confused with other tick-borne patho-
gens, either because of its comparable symptoms or because of
misinterpretation of a serological reaction against an (endured)
co-infection.
Patient categories that have an (endured) infection with this
relapsing-fever spirochaete are expected to have a higher
seroprevalence than the general population. For other relaps-
ing fever Borreliae the majority of antibodies are directed
towards the variable major proteins (VMP) [16]. However,
antibodies to VMP have been shown to be cross-reactive to
B. burgdorferi s.l. antigens. Furthermore, VMP is a highly
variable protein that could give false-negative results in
serological tests [16]. On the other hand, glycerophosphodi-
ester phosphodiesterase (GlpQ) appears to be highly con-
served among all members of the relapsing fever Borreliae,
including B. miyamotoi, but distinct for the spirochaetes causing
LB and their near relatives. In addition, GlpQ is immunogenic
in humans and shows negative results when testing sera from
LB and syphilis patients [16–20]. More recently, an American
study showed that serum samples from 1% to 3% of residents
of New England were reactive in an experimental serological
assay targeting the B. miyamotoi GlpQ antigen [21].
The long-term objective of our studies is to gain more insight
into the public health risk of B. miyamotoi. As a ﬁrst attempt to
describe the exposure of B. miyamotoi in the Netherlands, using
a newly developed serological assay based on the GlpQ antigen,
we determined here the seroprevalence of anti-B. miyamotoi
antibodies in different risk groups within the general popula-
tion. Apart from important epidemiological insights, our
ﬁndings will facilitate the future identiﬁcation of the clinical
symptoms of B. miyamotoi infections and might serve as a
starting point for further development of serological assays.
Materials and Methods
Antigen preparations and biochemicals
A DNA sequence encoding for the B. miyamotoi GlpQ protein
was ampliﬁed from an I. ricinus lysate, cloned, sequence-
veriﬁed, expressed and puriﬁed from an Escherichia coli
construct (Scottish Biomedical, Glasgow, UK). Puriﬁed GlpQ
was coupled to activated carboxylated microspheres by using a
two-step carbodiimid reaction with an antigen to bead ratio of
50 lg/6.25 9 106 [22]. The beads were incubated in the dark
under constant rotation at 25 rpm for 2 h at room temper-
ature. The beads were washed three times with phos-
TABLE 1. Case reports of Borrelia miyamotoi infections associated with disease





Individuals admitted to hospital,
suspected for tick-borne
infection (n = 51)
4/51 Fever, headache, chills, fatigue, vomiting and myalgia
USA [21] Seroconversion Previously healthy
individuals (n = 3)
2/3 Fever, chills, sweats, headache, neck stiffness, fatigue, myalgias, arthralgias, abdominal





0/1 Meningoencephalitis, progressive decline in mental status, wobbling gait and difﬁculty
hearing, weight loss
USA [15] PCR 61-year-old male, anorexia Not
mentioned
Severe frontal headaches, photophobia, myalgia and arthralgia, pain across the chest,
muscles were tightening, sweats and episodes of fever with shaking chills
USA [15] PCR 87-year-old male, previously
healthy










Meningoencephalitis, complaints of confusion, altered personality and a disturbed gait,
unexplained chronic diarrhoea and bradyphrenic
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phate-buffered saline (PBS) and stored in 500 lL PBS contain-
ing 0.05% (weight/volume (w/v)) sodium azide and 1% (w/v)
bovine serum albumin at 4°C in the dark until used [23–25].
Biochemicals and reagents used were from Sigma (St Louis,
MO, USA), Pierce (Rockford, IL, USA), Bio-Rad Laboratories
(Hercules, CA, USA) and Merck (Darmstadt, Germany) and
were used in the highest purity available.
Serum samples
Sera from 150 blood donors were used as negative controls to
determine the background in the general Dutch population.
Ten sera of PCR-conﬁrmed B. miyamotoi patients were used as
positive controls and were described previously [12]. These
sera were also positive in a anti-GlpQ serological assay
developed and performed in Russia (not shown). Sera from
patients infected with Treponema pallidum were included to
test for possible cross-reactivity [26]. In total, 120 serum
samples from forestry workers were used as a group with high
exposure to tick bites [27,28]. Serum specimens from Lyme
neuroborreliosis (LNB) and HGA suspected patients were
obtained from the residuals of sera submitted to the National
Institute for Public Health and Environment (RIVM) for routine
microbiological investigations, provided the patients did not
object to this use by indicating this on the diagnostic request
form. Sera with no or doubtful epidemiological data and
repetitive sera were excluded. Selected sera were divided in
different patient groups: 54 individuals with serologically
conﬁrmed LNB based on the detection of local antibody
production in the paired liquor sample and 35 individuals with
serologically unconﬁrmed LNB. In addition, 130 samples from
patients sent in to our laboratory for HGA serology, but that
tested negative for IgG-speciﬁc and IgM-speciﬁc HGA, were
also examined. Serological conﬁrmation for LB was based on
positive test results of B. burgdorferi s.l. Immunoblot (in house),
and C6-ELISA (Immunetics, Boston, MA, USA). Immunoﬂuo-
rescence assays against Anaplasma phagocytophylum and Ehrli-
chia chaffeensis (Focus Technologies, Cypress, CA, USA) were
used. ‘Serological unconﬁrmed’ was deﬁned as negative test
results in these serological assays.
Serological analysis
Antibodies to the GlpQ protein of B. miyamotoi were deter-
mined by an in-house Luminex assay. Serum dilutions and
conjugate concentrations in the Luminex assay were optimized
using checkerboard titrations. Sera and positive and negative
control samples were tested in duplicate or triplicate and were
diluted 1 : 200 in 25 lL PBS containing 0.1% (v/v) Tween-20 and
3% (w/v) bovine serumalbumin. Serum samplesweremixedwith
an equal volume of GlpQ-conjugated microspheres
(4000 beads/region/well) in a 96-well Multiscreen HTS ﬁlter
plate (Millipore Corporation, Billerica, MA, USA) and incubated
on a plate shaker at 600 rpm in the dark for 45 min at room
temperature. Blank and control sera were included on every
plate. The beads were collected by ﬁltration using a vacuum
manifold andwashed three timeswith 100 lL PBS. To eachwell,
50 lL of a 1 : 200 dilution of R-phycoerthyryn-conjugated goat
anti-human IgG (Jackson ImmunoResearch Laboratories, West-
grove, PA, USA) in PBS was added and the plate was incubated
for 30 min with continued shaking. After a second wash, the
beads were resuspended in 100 lL PBS and shaken before
analysis with a Bio-Plex 200 in combination with BIO-PLEX
MANAGER software version 4.1.1 (Bio-Rad Laboratories).
Statistical analysis
The Kolmogorov–Smirnov test was used to test null hypoth-
eses that the LogOD values of different groups were normally
distributed. Fisher’s exact test was used to calculate the 95%
CI. A one-tailed Fisher’s exact test was used to compare
pairwise the frequency of B. miyamotoi seropositive and
seronegative subjects in different groups. The level of signif-
icance was set at p <0.05. Moreover, Taylor series was used to
calculate OR with a 95% CI testing.
Results
All serum samples (n = 513) were tested for their reactivity
against the GlpQ protein of the European B. miyamotoi. The
LogOD values of the samples from 150 blood donors were
normally distributed (p 0.56), whereas the LogOD values of all
samples from the risk groups were not (p <0.004), indicating
that the latter distribution is the mixture of two distributions
(not shown). To strive for a relatively high speciﬁcity, a cut-off
value of two standard deviations above the average of the
blood donor group (n = 150) was chosen. This is in line with
recommendations by the CDC to conﬁrm the diagnosis of tick
borne relapsing fever in the USA. With this chosen cut-off
(LogOD 3.50), the seroprevalence of B. miyamotoi IgG anti-
bodies in blood donors was 2.0% (Table 2) and nine out of the
ten sera from conﬁrmed B. miyamotoi-infected patients from
Russia were also serologically positive. Only one out of 24
serum samples from patients infected with an unrelated
spirochaete, Treponema pallidum, showed reactivity against
the GlpQ antigen, and the seroprevalence in this category was
comparable to that of the blood donors. Although an increase
in seroprevalence was observed comparing blood donors to
conﬁrmed and unconﬁrmed LNB patients, these seropreva-
lences did not differ signiﬁcantly from that of the blood donors
(Table 2). In the serologically unconﬁrmed but suspected HGA
group a signiﬁcantly higher seroprevalence was observed
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compared with that in the blood donor panel. In addition, the
seroprevalence in forestry workers was signiﬁcantly higher
than the seroprevalence in blood donors (Table 2).
Discussion
This study provides serological evidence of B. miyamotoi
exposure in humans in the Netherlands using the GlpQ
antigen of B. miyamotoi in a newly developed assay. Based on
the signiﬁcantly higher anti-B. miyamotoi antibodies in forestry
workers and the serologically unconﬁrmed but suspected
HGA group, B. miyamotoi infection appears not only to occur
in immunocompromised patients, as has recently been
described in the Netherlands [14], but also seems to affect
populations without underlying or chronic disease, which is in
line with recent studies [12,15,21].
The seroepidemiology of the prevalence of IgG antibodies
against B. miyamotoi as evidence for (endured) infection was
examined in this study. Therefore, the study was set up to
determine the seroprevalence in the different populations at a
given moment, a cross-sectional design, determining B. miy-
amotoi exposure rather than infection. No discrimination
between endured or active infection was made, we did not
determine a rise, decline or persistence of speciﬁc antibody
production in these individuals nor did we determine the
presence of anti-B. miyamotoi IgM antibodies. According to
the CDC, to conﬁrm the clinical diagnosis of other tick-borne
relapsing fevers caused by B. hermsii, Borrelia parkerii or
Borrelia turicatae, speciﬁc antibody titres should increase
fourfold between acute and convalescent serum samples.
Because of the cross-sectional design of this study, no
convalescent serum samples were tested and therefore we
were not able to assess the course of the serological
response over time. Patients with other tick-borne relapsing
fevers may have false-positive tests in indirect immunoﬂuo-
rescence assay or whole lysate ELISA for LB because of the
similarity of proteins between the two organisms. Because of
the inherent disadvantages of cultivation and PCR-based
methods as diagnostic tools, a serological test such as the one
we describe here is an important step towards a new
diagnostic tool.
Our aim was to identify risk groups with signiﬁcantly more
exposure than the general population. As recommended by
the CDC we used a cut-off two standard deviations above the
average of the blood donor group in order to strive for a
relatively high speciﬁcity. This is higher than the mathematical
optimal cut-off value (LogOD 3.45), which gives the best
discrimination between positive and negative serum samples,
yet without taking false-positivity into account (data not
shown). Nonetheless, assays for exposure to B. miyamotoi,
such as described here and for other recombinant GlpQ
antigen ELISA and immunoblots described before [21], need to
be more extensively validated and tested to determine the
speciﬁcity and sensitivity. In the Netherlands, we have not
identiﬁed another relapsing fever spirochaete other than
B. miyamotoi in ticks obtained from the environment, so far.
Therefore, we assume that cross-reactivity between different
relapsing fever GlpQ [16] has no, or an insigniﬁcant, inﬂuence
in the Dutch setting. In addition, no signiﬁcant cross-reactivity
was observed with T. pallidum-positive patients.
An increased seroprevalence was observed in unconﬁrmed
and conﬁrmed LNB patients, which might be attributed to
exposure to ticks infected with both B. burgdorferi s.l. and
B. miyamotoi [11,14]. Whether co-infection with B. miyamotoi
exists and may alter the clinical manifestations of LB or LNB
remains to be answered, our serological evidence suggest that
it can occur in the same patients, assuming that patients were
diagnosed correctly. From our data we cannot conclude
whether these were concomitant or serial infections. It should
be mentioned that, in analogy to B. burgdorferi s.l. infection in
Europe, it might also be that anti-B. miyamotoi antibodies are a
result of a previous asymptomatic infection. To answer these
questions a longitudinal approach would be required.
Previous studies conducted in the Netherlands showed that
forestry workers have an increased risk of acquiring infections
transmitted by ticks [27–30]. In this study, 11.6% (6.5–18.8%)
of the forestry workers tested positive for anti-B. miyamotoi
TABLE 2. Seroprevalence using Borrelia miyamotoi GlpQ













Fisher exact test OR 95% CI
Blood donors (background) 150 3 2.0% 0.4–5.7% NA NA
Forestry workers (high risk) 120 12 10% 5.3–16.8% 0.005 5.44 1.5–19.76
LNB; serologically conﬁrmed 54 4 7.4% 2.0–17.9% 0.08 3.92 0.85–18.12
LNB; serologically unconﬁrmed 35 3 8.6% 1.8–23.0% 0.08 4.60 0.89–23.81
HGA; serologically unconﬁrmed 130 19 14.6% 9.0–21.8% <0.001 8.40 2.42–29.05
Treponema pallidum infection,
conﬁrmed
24 1 4.2% 0.2–18.9% 0.45
Signiﬁcant p-values (Fisher’s exact test, level of signiﬁcance was set at p <0.05) and OR (Taylor series, with 95% CI) in bold.
Abbreviations: GlpQ, Glycerophosphodiester phosphodiesterase; NA, not applicable; LNB, Lyme neuroborreliosis; HGA, human granulocytic anaplasmosis.
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IgG antibodies. These ﬁndings indicate that in addition to LB
and other tick-borne pathogens, forestry workers also run an
occupational risk of acquiring infection with B. miyamotoi or at
least being exposed to this tick-borne pathogen. Furthermore,
based on the ﬁndings presented here, demonstrating that the
group of patients with suspected HGA have a signiﬁcantly
higher seropositivity compared with blood donors, it is
suggested that B. miyamotoi might also cause a febrile illness
comparable to HGA. This is in line with previous case reports
[15]. Indeed, the clinical manifestations of HGA might be
similar to those caused by B. miyamotoi infection, including
(high-grade) fever, chills, myalgia, nausea and headache a few
weeks after a tick bite. Therefore, clinicians should include
B. miyamotoi in the differential diagnosis of patients with a
febrile illness caused by an unknown aetiological agent when
there is evidence of tick exposure.
In conclusion, a Luminex-assay was developed for seroepide-
miological screening of IgG antibodies against the GlpQ protein
of B. miyamotoi. We observed an increase in seroprevalence
from blood donors compared with unconﬁrmed and conﬁrmed
LNB patients. However, only the forestry workers and the
serologically unconﬁrmed but suspected HGA group consis-
tently showed signiﬁcantly higher seroprevalence compared
with the blood donor panel. It could be that some patients
identiﬁed ashaving LB anddeﬁnitely some thatwere suspectedof
having HGA, substantiated in part by non-speciﬁc serological
tests such as a whole-cell ELISA or not substantiated at all, may
actually have been infected with these relapsing fever spirochae-
tes. Furthermore, our study suggests that individuals that are
(occupationally) exposed to ticks in the Netherlands, such as
forestry workers, are potentially at risk for B. miyamotoi
infection. Interestingly, in light of the popularity of outdoor
recreational activities among Dutch people, it is to be expected
that this will certainly predispose a large number of people to the
risk of infection with B. miyamotoi, among other tick-borne
pathogens. Therefore, B. miyamotoi infection should be included
in the differential diagnosis when forestry workers or patients
who engage in outdoor recreational activity present with fever
after a tick bite. In addition, in patients with unexplained fever or
HGA-like symptoms after exposure to ticks, physicians should
consider B. miyamotoi infection. Until better validated diagnostic
tests become available it should be recommended to consult
academic referral centreswhen there is suspicionofB. miyamotoi
infection.
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